Anaplastic Lymphoma Kinase

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, Enriqueta Felip, Patrick Forde, Marina Garassino, Sarah Goldberg, Johan Vansteenkiste, Anthony Jarkowski, Stuart McIntosh, Luping Zhao, Scott Antonia

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P171; DOI: 10.1186/2051-1426-3-S2-P171
Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
Alec Walker, Paola Lopomo, William Babbitt, Marc Vigny, Crystal Mackall, Rimas Orentas

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P40; DOI: 10.1186/2051-1426-2-S3-P40
ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
Rimas J Orentas, Paola Lopomo, William Babbitt, Marc Vigny, Crystal L Mackall

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P27; DOI: 10.1186/2051-1426-1-S1-P27

Main menu